Centessa Pharmaceuticals plc (NASDAQ:CNTA) Short Interest Update

Centessa Pharmaceuticals plc (NASDAQ:CNTA) saw a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 4,150,000 shares, a growth of 36.1% from the January 31st total of 3,050,000 shares. Based on an average trading volume of 723,400 shares, the short-interest ratio is presently 5.7 days. Approximately 5.2% of the shares of the company are short sold.

Centessa Pharmaceuticals Price Performance

NASDAQ:CNTA traded up $0.47 during mid-day trading on Wednesday, hitting $16.80. The company’s stock had a trading volume of 682,076 shares, compared to its average volume of 816,547. The company has a market capitalization of $2.21 billion, a price-to-earnings ratio of -10.98 and a beta of 1.53. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals has a fifty-two week low of $7.75 and a fifty-two week high of $19.09. The stock has a fifty day moving average of $16.50 and a 200-day moving average of $16.09.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating for the company. Guggenheim reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $25.83.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, CTO Tia L. Bush sold 17,813 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $18.00, for a total transaction of $320,634.00. Following the completion of the transaction, the chief technology officer now directly owns 147,615 shares in the company, valued at $2,657,070. The trade was a 10.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $15.93, for a total value of $876,150.00. Following the completion of the sale, the chief executive officer now directly owns 331,017 shares of the company’s stock, valued at $5,273,100.81. This represents a 14.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 446,682 shares of company stock worth $7,632,282 over the last ninety days. Company insiders own 11.59% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

A number of large investors have recently bought and sold shares of CNTA. GF Fund Management CO. LTD. acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter worth approximately $31,000. Mirae Asset Global Investments Co. Ltd. raised its position in Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after purchasing an additional 826 shares during the last quarter. GAMMA Investing LLC boosted its stake in Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after purchasing an additional 865 shares in the last quarter. Barclays PLC grew its holdings in shares of Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after purchasing an additional 4,952 shares during the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at $162,000. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.